1443 Results for "

Cdk

" in MedChemExpress (MCE) Product Catalog:
Products (1443)

1443 Results for "Cdk" in MCE Product Catalog:

  • Targets Recommended:
  • Recombinant Proteins Recommended:
25
25 Cited Publications
Cat. No.: HY-N0400
CAS No.: 632-85-9
Wogonin is a naturally occurring mono-flavonoid, can inhibit the activity of CDK8 and Wnt, and exhibits anti-inflammatory and anti-tumor effects.
loading...
    loading...
21
21 Cited Publications
Cat. No.: HY-130250
CAS No.: 2387704-62-1
Purity:  99.64%
Target:  

CDK Apoptosis

Research Areas:  

Cancer

SR-4835 is a potent, highly selective and ATP competitive dual inhibitor of CDK12/CDK13 (CDK12: IC50=99 nM, Kd=98 nM; CDK13: Kd=4.9 nM). SR-4835 acts in synergy with DNA-damaging chemotherapy and PARP inhibitors and provokes triple-negative breast cancer (TNBC) cell death .
loading...
    loading...
20
20 Cited Publications
Cat. No.: HY-101488
CAS No.: 1010100-07-8
Purity:  99.85%
CC-885, a cereblon (CRBN) modulator, acts as a molecular glue degrader targeting GSPT1 with a Kd of 350 nM. CC-885 binds to CRBN to alter the substrate specificity of the CRL4 E3 ligase, promoting the ubiquitination and proteasomal degradation of GSPT1, BNIP3L, PLK1, CDK4, IKZF1/3, GSPT2, WIZ, CHD7, GOLM1, CK1α and ETS1. CC-885 induces apoptosis, cell cycle arrest, transcriptional downregulation and antiproliferation in cancer cells. CC-885 is applicable to research related to relapsed/refractory acute myeloid leukemia, MYC-driven tumors, metastatic castration-resistant prostate cancer, multiple myeloma, hepatocellular carcinoma, glioblastoma, VHL-deficient clear cell renal cell carcinoma and non-small cell lung cancer .
loading...
    loading...
18
18 Cited Publications
Cat. No.: HY-50943
CAS No.: 902135-91-5
Target:  

CDK Apoptosis

Research Areas:  

Cancer

AT7519 Hydrochloride is a potent inhibitor of CDKs, with IC50s of 210, 47, 100, 13, 170, and <10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK9, respectively.
loading...
    loading...
18
18 Cited Publications
Cat. No.: HY-50940
CAS No.: 844442-38-2
Synonyms: AT7519M
Target:  

CDK Apoptosis

Research Areas:  

Cancer

AT7519 (AT7519M) as a potent inhibitor of CDKs, with IC50s of 210, 47, 100, 13, 170, and <10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK9, respectively.
loading...
    loading...
18
18 Cited Publications
Cat. No.: HY-50940A
CAS No.: 1431697-85-6
Synonyms: AT7519M TFA
Target:  

CDK

Research Areas:  

Cancer

AT7519 (AT7519M) TFA as a potent inhibitor of CDKs, with IC50s of 210, 47, 100, 13, 170, and <10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK9, respectively.
loading...
    loading...
18
18 Cited Publications
Cat. No.: HY-12302
CAS No.: 142273-20-9
Purity:  98.20%
Synonyms: 9-Bromopaullone; NSC-664704
Target:  

CDK GSK-3

Research Areas:  

Cancer

Kenpaullone is a potent inhibitor of CDK1/cyclin B and GSK-3β, with IC50s of 0.4 μM and 23 nM, and also inhibits CDK2/cyclin A, CDK2/cyclin E, and CDK5/p25 with IC50s of 0.68 μM, 7.5 μM, 0.85 μM, respectively. Kenpaullone, a small molecule inhibitor of KLF4, reduces self-renewal of breast cancer stem cells and cell motility in vitro.
loading...
    loading...
18
18 Cited Publications
Cat. No.: HY-15532
CAS No.: 891494-63-6
Purity:  99.81%
Synonyms: MK-8776
Research Areas:  

Cancer

SCH900776 (MK-8776) is a potent, selective and orally bioavailable inhibitor of checkpoint kinase1 (Chk1) with an IC50 of 3 nM. SCH900776 shows 50- and 500-fold selectivity over CDK2 and Chk2, respectively .
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-101257
CAS No.: 1957203-01-8
Purity:  98.79%
Target:  

CDK

Research Areas:  

Cancer

YKL-5-124 is a potent, selective, irreversible and covalent CDK7 inhibitor with IC50s of 53.5 nM and 9.7 nM for CDK7 and CDK7/Mat1/CycH, respectively. YKL-5-124 is >100-fold greater selective for CDK7 than CDK9 and CDK2, and inactive against CDK12 and CDK13. YKL-5-124 induces a strong cell-cycle arrest, inhibits E2F-driven gene expression, and exhibits little effect on RNA polymerase II phosphorylation status .
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-101257B
CAS No.: 2748220-93-9
Purity:  99.74%
Target:  

CDK

Research Areas:  

Cancer

YKL-5-124 TFA is a potent, selective, irreversible and covalent CDK7 inhibitor with IC50s of 53.5 nM and 9.7 nM for CDK7 and CDK7/Mat1/CycH, respectively. YKL-5-124 TFA is >100-fold greater selective for CDK7 than CDK9 and CDK2, and inactive against CDK12 and CDK13. YKL-5-124 TFA induces a strong cell-cycle arrest, inhibits E2F-driven gene expression, and exhibits little effect on RNA polymerase II phosphorylation status .
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-10580
CAS No.: 667463-62-9
Purity:  99.31%
Synonyms: 6-Bromoindirubin-3'-oxime; BIO; MLS 2052
Target:  

GSK-3 CDK Apoptosis

Research Areas:  

Cancer

GSK 3 Inhibitor IX (6-Bromoindirubin-3'-oxime; BIO) is a potent, selective, reversible and ATP-competitive inhibitor of GSK-3α/β and CDK1-cyclinB complex with IC50s of 5 nM/320 nM/80 nM for (GSK-3α/β)/CDK1/CDK5, respectively.
loading...
    loading...
16
16 Cited Publications
Cat. No.: HY-10012
CAS No.: 602306-29-6
Purity:  99.91%
Target:  

CDK

Research Areas:  

Cancer

AZD-5438 is a potent CDK1, CDK2, and CDK9 inhibitor, with IC50s of 16 nM, 6 nM, and 20 nM in cell-free assays, respectively. AZD-5438 shows less inhibition activity against GSK3β, CDK5 and CDK6 .
loading...
    loading...
15
15 Cited Publications
Cat. No.: HY-103248
CAS No.: 606-58-6
Purity:  99.78%
Synonyms: Vengicide
Toyocamycin (Vengicide) is an adenosine analog produced by Streptomyces diastatochromogenes, acts as an XBP1 inhibitor. Toyocamycin blocks RNA synthesis and ribosome function, and induces apoptosis. Toyocamycin affects IRE1α-XBP1 pathway, and inhibits XBP1 mRNA cleavage with an IC50 value of 80 nM with affecting IRE1α auto-phosphorylation. Toyocamycin specifically inhibits CDK9 with an IC50 value of 79 nM .
loading...
    loading...
15
15 Cited Publications
Cat. No.: HY-11012
CAS No.: 327036-89-5
Purity:  99.76%
Synonyms: GSK-3β Inhibitor I; NP 01139
Target:  

GSK-3

Research Areas:  

Cancer

TDZD-8 is an inhibitor of GSK-3β, with an IC50 of 2 μM; TDZD-8 shows less potent activities against Cdk-1/cyclin B, CK-II, PKA, and PKC, with all IC50s of >100 μM.
loading...
    loading...
14
14 Cited Publications
Cat. No.: HY-124719
CAS No.: 1402452-15-6
Purity:  99.82%
Target:  

PI3K mTOR GSK-3 CDK

Research Areas:  

Cancer

hSMG-1 inhibitor 11j, a pyrimidine derivative, is a potent and selective inhibitor of hSMG-1, with an IC50 of 0.11 nM. hSMG-1 inhibitor 11j exhibits >455-fold selectivity for hSMG-1 over mTOR (IC50=50 nM), PI3Kα/γ (IC50=92/60 nM) and CDK1/CDK2 (IC50=32/7.1 μM). hSMG-1 inhibitor 11j can be used for the research of cancer .
loading...
    loading...
14
14 Cited Publications
Cat. No.: HY-12467
CAS No.: 1338545-07-5
Purity:  99.74%
Target:  

TOPK CDK Apoptosis

Research Areas:  

Cancer

OTS964 hydrochloride is an orally active, high affinity and selective TOPK (T-lymphokine-activated killer cell-originated protein kinase) inhibitor with an IC50 of 28 nM . OTS964 hydrochloride is also a potent inhibitor of the cyclin-dependent kinase CDK11, which binds to CDK11B with a Kd of 40 nM .
loading...
    loading...
14
14 Cited Publications
Cat. No.: HY-112088
CAS No.: 2057509-72-3
Purity:  99.98%
Target:  

CDK

Research Areas:  

Cancer

AZD4573 is a potent and highly selective CDK9 inhibitor (IC50 of <4 nM) that enables transient target engagement for the treatment of hematologic malignancies .
loading...
    loading...
13
13 Cited Publications
Cat. No.: HY-15878
CAS No.: 1073485-20-7
Purity:  98.09%
Synonyms: LDC067
Target:  

CDK Apoptosis

Research Areas:  

Cancer

LDC000067 is a highly specific CDK9 inhibitor with an IC50 value of 44±10 nM in vitro.
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-103712
CAS No.: 1805833-75-3
Synonyms: CT7001; ICEC0942
Target:  

CDK Apoptosis

Research Areas:  

Cancer

Samuraciclib (CT7001) is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC50 of 41 nM. Samuraciclib displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC50 of 578 nM), CDK5 and CDK9, respectively. Samuraciclib inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 μM. Samuraciclib has anti-tumor effects .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-103712A
CAS No.: 1805789-54-1
Purity:  99.90%
Synonyms: CT7001 hydrochloride; ICEC0942 hydrochloride
Target:  

CDK Apoptosis

Research Areas:  

Cancer

Samuraciclib hydrochloride (CT7001 hydrochloride) is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC50 of 41 nM. Samuraciclib hydrochloride displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC50 of 578 nM), CDK5 and CDK9, respectively. Samuraciclib hydrochloride inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 µM. Samuraciclib hydrochloride has anti-tumor effects .
loading...
    loading...